Given its ability to differentiate high and low Stage I disease, we think that AKR1B10 may be a protein whose expression in breast cancer tissues can further categorize this intermediate risk group of breast cancer patients and aid the clinician in the decision to administer chemotherapy. This evidence concerns the gene AKR1B10 and breast cancer.